

Application No. 10/537,645  
Amendment dated December 18, 2007  
Reply to Office action of November 16, 2007

**Amendments to the Specification:**

On page 1, please delete the current title and add the new title:

**CRYSTALLINE DERIVATIVES OF (E)-2-(5-CHLOROTHIEN-2-YL)-N-((3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE**

On page 3 at line 28, please insert the following heading and paragraphs:

**Brief Description of the Several Views of the Drawing(s)**

Figure 1 shows the X-Ray Powder Diffractogram of substantially crystalline (E)-2-(5-Chlorothien-2-yl)-N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethenesulfonamide prepared according to Example 1.

Figure 2 shows the X-Ray Powder Diffractogram of substantially crystalline (E)-2-(5-Chlorothien-2-yl)-N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethenesulfonamide prepared according to Example 2.